| abstract |
Use of an antagonist that specifically binds to a denatured collagen or collagen but binds to the native triple helix form of each of said collagen or collagen with substantially reduced affinity, wherein said antagonist inhibits angiogenesis, wherein said Antagonist is an antibody for the manufacture of a composition for the inhibition of angiogenesis in a tissue induced by inflammation, psoriasis, macular degeneration or restenosis or during tumor growth or metastasis. |